Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Bawkeron Feb 14, 2019 6:08pm

124 Views

Post# 29367274

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Shares outstanding: 216,555,761

I questioned why it went from the 291-214M...easy to follow how KALY went up to current share count (both diluted and not) but I still find it odd its showing 214M. It WAS 290M and was changed down to 214M so its not 'out dated'.

TMX website shows this 'error' as well - TMX

But yes, according to Bob still at ~290M shares undiluted

MAZZMEX wrote: So i guess the "hater"(me), was right after all...srating facts is not bashing...

Bawker wrote:

Bawker wrote: Huh? Shares out has been increasing with each Salzman issue and the PPs...thats how we got up to 291M shares...The dilution from the Salzman shares and price drop wouldnt occur each month if the shares weren't common shares on market... they are and were included in the total

Spoke with Bob this afternoon...he told me as far as hes concerned it is in fact just a mistake and the number of shares out is 290.47M as of his last report...fully diluted just under 373M.

He also said:

Still on time to finish first group Feb 28th

Had second trial patients lined up and starting process now the higher dosage has been approved.

Confirmed that this second trail with higher dosage should be even more effective. Also no foreseeable issues with highest (3rd) dosage for tolerability.

P3 still to start by end of 2019.

No update on pain program at moment but still obviously working on it.

Overall very happy but still find the share count odd. Can someone please post level 2 for the warrants?